Can it get any worse for Novartis’ U.S. stock? The Swiss company said Tuesday that del-desiran, part of a recent acquisition, reached the end of the line in a trial for a rare neuromuscular disease. The drugmaker’s U.S.-listed shares slumped 13% to $139.01 Tuesday. Continue Reading
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.